Colo-rectal CancerNCT03623152
Colorectal Neoplasia and Microbiota: Does Left Equal Right?
An observational study of Colo-rectal Cancer, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
Many studies, including our own, have shown that colorectal cancer (CRC) is related to changes in the microbiome of the colon. However, there are limitations in most studies and questions remained unanswered. Some early data showing that the microbiome in the left vs right colon are different. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colo-rectal Cancer
- How many people
- 160 participants
- Where
- 1 siteHong Kong
- Study dates
- 7 Aug 2018to 6 Oct 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients have scheduled colonoscopy
Who may be able to join
- >18 years of age, with the informed consent of the study-specific colonoscopy examination method and samples collection
- have an indication for a scheduled colonoscopy, either as an investigation of colorectal symptom or as part of a CRC screening
- for those who are known to have either adenoma or CRC, colonoscopy is arranged for endoscopic submucosal dissection (ESD) or endoscopic mucosectomy (EMR)
Who cannot join
- known history of coagulopathy b. recently on antithrombotics or antiplatelets c. recently on antibiotics, prebiotics, probiotics and symbiotics d. anticipated prolonged standard colonoscopy procedure at endoscopist's discretion e. consent cannot be obtained
- -
Trial locations and contacts
1 site in 1 country.
Hong Kong1 site, 1 recruiting
- Recruiting
Endoscopy Center, Prince of Wales Hospital
Hong Kong
Fanny Cheung', 35052231
About this study
Many studies, including our own, have shown that colorectal cancer (CRC) is related to changes in the microbiome of the colon. However, there are limitations in most studies and questions remained unanswered. Some early data showing that the microbiome in the left vs right colon are different.
The aim of this study is to investigate the microbiome (including bacteriome, virome, and fungome) of adenoma/CRC comparing the left (distal to splenic flexure) vs right side (proximal to splenic flexure) of the colon.
Read the detailed description
- Many studies, including our own, have shown that colorectal cancer (CRC) is related to changes in the microbiome of the colon
- Certain bacterial phyla are more frequently presented in CRC
- Bacterial diversity is reduced in CRC
- Co-occurrence of bacterial phyla and exclusion are identified in CRC
- Besides bacteriome, viromes have been found associated with CRC
- These changes in the pattern may actually be used for diagnosis and prognosticate purposes.
- However, there are limitations in most studies and questions remained unanswered
- Most studies used stool sample and data of tissue (tumor and adjacent normal tissues) may not be available
- Most studies take adenoma and CRC as one condition, without differentiating the findings according to tumor location
- Most studies have separate bacteria, virus and fungi. There is a lack of data on their interaction
- Most studies have identified either microbiome without correlating them with the genomic of the host
- We know that not all CRC are the same. It has been known that rectal and colonic cancer are not the same. Furthermore, proximal (right) CRC and distal (left) CRC may not be the same.
- Studies have shown compare to L-CRC, patients with R-CRC are older, more female (Iaocopetta B et al. Int J Cancer 2002)
- Studies have also shown that the genomic make up of L-CRC and R-CRC are different. R-CRC are more likely to have family cancer syndrome (HNPCC), mostly diploid, less frequent to have loss heterozygosity, less TP53 mutations and more MSI and CIMP, and the gene expression are different (Glebov et al. Cancer Epi, Biomarker and Prevention 2003)
- The response to therapy might also be different in the L-CRC compare to R-CRC
- Recent studies show that the clinico-pathological and molecular features of early-onset (<50 years) CRC varies according to tumor location. (Peres J et al. Am J Cancer Res 2015). In the R-CRC in this group, germline mutation is more common (MLH1, MSH2, MSH6, PMS2 and EPCAM). Adenomas tend to be larger, flatter and more likely to have high-grade dysplasia and villous histology
- Recent studies have also shown that the clinic-pathological and molecular feature of in the late-onset CRC (70-80 years) varies with tumor location (Brandariz et al. Oncotarget 2018). There are more sporadic MSI, more BRAF mutation and the adenoma/CRC are likely to be mucinous.
- Studies comparing the microbiome of L-CRC vs R-CRC has not been many. There is some early data showing that the microbiome in the left vs right colon are different.
The aim of this study is to investigate the microbiome (including bacteriome, virome, and fungome) of adenoma/CRC comparing the left (distal to splenic flexure) vs right side (proximal to splenic flexure) of the colon.
- Conditions
- Colo-rectal Cancer
- Medical subject headings
- Colonic Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Descriptive statistics will be used for demographics data
Since the sample size is small, non-parametric chi-square test or Mann-Whitney tests will be used for the comparison of the clinical data between the cases with adenoma or CRC on the right and left side colon.
Measured: All biological samples will be stored for a maximum of 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2018
- Study start7 Aug 2018
- Primary completion6 Sep 2019 (estimated)
- Study completion6 Oct 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colo-rectal CancerStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joseph JY SUNG, Chinese University of Hong Kong
- Investigators
- Joseph JY Sung, Principal investigator, Chinese Univeristy of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03623152
- Sponsor's protocol ID
- CRC MIC L&R
- Status last verified
- Jul 2019
- First submitted
- 7 Aug 2018
- Last updated
- 24 Jul 2019
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Colorectal Neoplasia and Microbiota: Does Left Equal Right?
- ClinicalTrials.gov ID
- NCT03623152
- Acronym / sponsor ID
- CRC MIC L&R
- Conditions
- Colo-rectal Cancer
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 160 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 7 Aug 2018 (actual)
- Primary completion
- 6 Sep 2019 (estimated)
- Study completion
- 6 Oct 2019 (estimated)
- First posted
- 9 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Many studies, including our own, have shown that colorectal cancer (CRC) is related to changes in the microbiome of the colon. However, there are limitations in most studies and questions remained unanswered. Some early data showing that the microbiome in the left vs right colon are different.
The aim of this study is to investigate the microbiome (including bacteriome, virome, and fungome) of adenoma/CRC comparing the left (distal to splenic flexure) vs right side (proximal to splenic flexure) of the colon.
Detailed description
- Many studies, including our own, have shown that colorectal cancer (CRC) is related to changes in the microbiome of the colon
- Certain bacterial phyla are more frequently presented in CRC
- Bacterial diversity is reduced in CRC
- Co-occurrence of bacterial phyla and exclusion are identified in CRC
- Besides bacteriome, viromes have been found associated with CRC
- These changes in the pattern may actually be used for diagnosis and prognosticate purposes.
- However, there are limitations in most studies and questions remained unanswered
- Most studies used stool sample and data of tissue (tumor and adjacent normal tissues) may not be available
- Most studies take adenoma and CRC as one condition, without differentiating the findings according to tumor location
- Most studies have separate bacteria, virus and fungi. There is a lack of data on their interaction
- Most studies have identified either microbiome without correlating them with the genomic of the host
- We know that not all CRC are the same. It has been known that rectal and colonic cancer are not the same. Furthermore, proximal (right) CRC and distal (left) CRC may not be the same.
- Studies have shown compare to L-CRC, patients with R-CRC are older, more female (Iaocopetta B et al. Int J Cancer 2002)
- Studies have also shown that the genomic make up of L-CRC and R-CRC are different. R-CRC are more likely to have family cancer syndrome (HNPCC), mostly diploid, less frequent to have loss heterozygosity, less TP53 mutations and more MSI and CIMP, and the gene expression are different (Glebov et al. Cancer Epi, Biomarker and Prevention 2003)
- The response to therapy might also be different in the L-CRC compare to R-CRC
- Recent studies show that the clinico-pathological and molecular features of early-onset (<50 years) CRC varies according to tumor location. (Peres J et al. Am J Cancer Res 2015). In the R-CRC in this group, germline mutation is more common (MLH1, MSH2, MSH6, PMS2 and EPCAM). Adenomas tend to be larger, flatter and more likely to have high-grade dysplasia and villous histology
- Recent studies have also shown that the clinic-pathological and molecular feature of in the late-onset CRC (70-80 years) varies with tumor location (Brandariz et al. Oncotarget 2018). There are more sporadic MSI, more BRAF mutation and the adenoma/CRC are likely to be mucinous.
- Studies comparing the microbiome of L-CRC vs R-CRC has not been many. There is some early data showing that the microbiome in the left vs right colon are different.
The aim of this study is to investigate the microbiome (including bacteriome, virome, and fungome) of adenoma/CRC comparing the left (distal to splenic flexure) vs right side (proximal to splenic flexure) of the colon.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients have scheduled colonoscopy
Key inclusion criteria (3 listed)
- >18 years of age, with the informed consent of the study-specific colonoscopy examination method and samples collection
- have an indication for a scheduled colonoscopy, either as an investigation of colorectal symptom or as part of a CRC screening
- for those who are known to have either adenoma or CRC, colonoscopy is arranged for endoscopic submucosal dissection (ESD) or endoscopic mucosectomy (EMR)
Key exclusion criteria (2 listed)
- known history of coagulopathy b. recently on antithrombotics or antiplatelets c. recently on antibiotics, prebiotics, probiotics and symbiotics d. anticipated prolonged standard colonoscopy procedure at endoscopist's discretion e. consent cannot be obtained
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Descriptive statistics will be used for demographics data
Time frame: All biological samples will be stored for a maximum of 10 years
Since the sample size is small, non-parametric chi-square test or Mann-Whitney tests will be used for the comparison of the clinical data between the cases with adenoma or CRC on the right and left side colon.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Colo-rectal Cancer
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1
A Study of MGC030 in Participants With Advanced Solid Tumors
Urothelial Cancer, GastroEsophageal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 1/2
LYL273 for Patients With Relapsed or Refractory mCRC
Colorectal Cancer
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joseph JY Sung principal investigator
Chinese Univeristy of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colo-rectal Cancer, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yuet Ling Ching (35053524, jessicaching@cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Descriptive statistics will be used for demographics data (time frame: All biological samples will be stored for a maximum of 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2019.